Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will be used to support the preclinical and clinical development a of a novel brain-penetrating small molecule NPT1220-478, Toll-Like receptor 2 antagonist and maintaining a harmful neuro- inflammatory condition in Parkinson’s disease.
Lead Product(s): NPT1220-478
Therapeutic Area: Neurology Product Name: NPT1220-478
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michael J. Fox Foundation for Parkinson’s Research
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Funding April 19, 2022
Details:
UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration entered into between Neuropore Therapies and UCB Biopharma on December, 2014. This milestone payment is a result of the continued clinical progress of UCB0599.
Lead Product(s): UCB0599
Therapeutic Area: Neurology Product Name: UCB0599
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: $460.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2021
Details:
The funding will support the preclinical evaluation and development of Neuropore's leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): NPT1220-312
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: ALS Association
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding February 17, 2020
Details:
The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.
Lead Product(s): NPT520-34
Therapeutic Area: Neurology Product Name: NPT520-34
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Celerion
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020